Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Meeting Abstract
| Authors: | Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M.; Wang, M.; Arnason, J. E.; Kamdar, M.; Maloney, D. G.; Shadman, M.; Andreadis, C.; Sehgal, A. R.; Solomon, S. R.; Ghosh, N.; Hidalgo-López, J. E.; Wang, J.; Ogasawara, K.; Singh, A.; Siddiqi, T. |
| Abstract Title: | Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3125 |
| Language: | English |
| ACCESSION: | WOS:001412771300025 |
| DOI: | 10.1182/blood-2024-200204 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
